miércoles, 28 de marzo de 2012

Weight-loss surgery cut blood sugar more than drugs: MedlinePlus

Weight-loss surgery cut blood sugar more than drugs: MedlinePlus

Weight-loss surgery cut blood sugar more than drugs

URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_123399.html
 (*this news item will not be available after 06/24/2012)

Monday, March 26, 2012Reuters Health Information Logo
Related MedlinePlus Pages
By Debra Sherman and Ransdell Pierson
CHICAGO (Reuters) - Weight-loss surgery did a better job of controlling type 2 diabetes in overweight and moderately obese patients than the most advanced medical treatment for the disease, researchers said on Monday.
The study, conducted at the Cleveland Clinic and presented at the annual scientific sessions of the American College of Cardiology in Chicago, showed that patients who underwent surgery were more than three times more likely to gain control over their diabetes after one year than the group that was treated with drugs.
Uncontrolled diabetes is a major risk factor for heart problems, including heart attack.
"Within days and hours of surgery -- before there's any measurable weight loss -- we saw dramatic changes. A majority of(surgery) patients left the hospital with normal blood sugars. However, this was not as effective for people who had diabetes for many years," said Dr. Philip Schauer, director of Bariatric and Metabolic Institute at the Cleveland Clinic, who led the clinical trial.
Shauer called the findings, which were published in the New England Journal of Medicine, "a potential paradigm change" for how some patients should be treated for diabetes.
In the study, dubbed STAMPEDE, researchers randomly assigned 150 patients -- three-quarters of them female -- with a body mass index between 27 and 43 into one of three groups.
There were two surgery groups -- laparoscopic gastric bypass, a surgery that reroutes the digestive system and allows food to bypass part of the small intestine, and sleeve gastrectomy, a procedure that reduces the stomach to about one- quarter of its original size.
The two surgery groups were compared with a third group that got the most advanced non-insulin treatment for diabetes, such as liraglutide, marketed by Novo Nordisk under the brand name Victoza.
The research was primarily funded by Johnson & Johnson's Ethicon Endo-Surgery Inc, a maker of surgical instruments used for bariatric surgery.
The main goal of the study was to reduce blood-sugar levels as measured by a test called HbA1c, a standard tool used to determine blood-sugar control in patients known to have diabetes. The America Diabetes Association recommends an HbA1c goal of less than 7 percent.
Patients in all groups had an average HbA1c level of 9 percent. The study measured those patients who achieved levels 6 percent or lower after one year.
Researchers reported that 42 percent of patients who underwent gastric bypass surgery achieved that goal, compared with 37 percent of patients who got the sleeve gastrectomy. Just 12 percent of the patients in the drug group achieved that goal.
"This study shows, in this group of patients who have poorly controlled diabetes, surgery is more effective than medication alone," Schauer said in an interview. "More doctors who treat diabetes are going to think about surgery for these patients.
"The implication is that insurance companies might need to reconsider coverage. Right now, there's a brick wall at 35," he said, referring to the BMI threshold where insurers will cover surgery.
A BMI is a number that is calculated from a person's weight and height and provides a reliable indicator of body fat for most people.
Not surprisingly, weight loss was five times greater among those who had surgery than those who did not.
While there was only a small improvement in blood pressure and cholesterol, those in the surgery group were able to slowly get off their blood pressure and cholesterol-fighting medications.
About 80 percent of the 23 million Americans living with type 2 diabetes are overweight or obese.
Dr. Steven Nissen, head of Cardiology at the Cleveland Clinic and another investigator on the STAMPEDE study, said half of the patients in his hospital's critical care unit are diabetic, which is typical of most hospitals in the United States.
"One percent of people in the weight range that would qualify for bariatric surgery are getting it. That could go up to 2 to 3 percent" on the basis of this study, Nissen said.
"If you do a $20,000 operation, what are the cost savings over time?" He said the Cleveland Clinic was following those patients from the study for five years to complete an economic study.
"I think more patients will be referred (for bariatric surgery) for consideration by their (insurance) carriers and more insurers will pay for bariatric surgery. They've thought of it as a cosmetic procedure, without considering the profound medical benefits" of the procedure.
He said it was frustrating to see those patients go down hill with vision loss, need for amputations, kidney dialysis and that he has gradually come to the conclusion that surgical procedures are warranted in some cases.
"Obesity has taken the country by storm and we have to stop it," he said.
(Reporting by Debra Sherman; Editing by Michele Gershberg and Maureen Bavdek)
Reuters Health
More Health News on:
Diabetes Type 2
Weight Loss Surgery

No hay comentarios:

Publicar un comentario